ArticleEvidence-based complementary and alternative medicine : eCAM2004
Traditional and Modern Biomedical Prospecting: Part II-the Benefits: Approaches for a Sustainable Exploitation of Biodiversity (Secondary Metabolites and Biomaterials from Sponges).
Article in Evidence-based complementary and alternative medicine : eCAM, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- Article
- Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Review
- Marine Natural Peptides: Determination of Absolute Configuration Using Liquid Chromatography Methods and Evaluation of Bioactivities.Molecules (Basel, Switzerland) · 2018Review
- Marine Sponges as a Drug Treasure.Biomolecules & therapeutics · 2016Review
- Modeling the distribution of Geodia sponges and sponge grounds in the Northwest Atlantic.PloS one · 2013Article
- Mumijo traditional medicine: fossil deposits from antarctica (chemical composition and beneficial bioactivity).Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Animal-based remedies as complementary medicines in the semi-arid region of northeastern Brazil.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Sustainable traditional medicine: taking the inspirations from ancient veterinary science.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Orthosiphon versus placebo in nephrolithiasis with multiple chronic complaints: a randomized control trial.Evidence-based complementary and alternative medicine : eCAM · 2009Article
- eCAM: Darwin and Metchnikoff.Evidence-based complementary and alternative medicine : eCAM · 2009Article
- eCAM: An Emerging Linkage with Ethnopharmacology?Evidence-based complementary and alternative medicine : eCAM · 2008Article
- On the Road to an Impact Factor for eCAM.Evidence-based complementary and alternative medicine : eCAM · 2007Article
- Streblus asper Lour. (Shakhotaka): A Review of its Chemical, Pharmacological and Ethnomedicinal Properties.Evidence-based complementary and alternative medicine : eCAM · 2006Article
- Tradition and perspectives of arab herbal medicine: a review.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- ECAM is waiting for eCAM.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- eCAM benefits from diversity that derives from CAM.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- CAM and cell fate targeting: molecular and energetic insights into cell growth and differentiation.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- CAM, eCAM, Bioprospecting: The 21st Century Pyramid.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- Bioprospecting: a CAM Frontier.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- Drug Discovery, CAM and Natural Products.Evidence-based complementary and alternative medicine : eCAM · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progress in molecular and cell biology has enabled a rational exploitation of the natural resources of the secondary metabolites and biomaterials from sponges (phylum Porifera). It could be established that these natural substances are superior for biomedical application to those obtained by the traditional combinatorial chemical approach. It is now established that the basic structural and functional elements are highly conserved from sponges to the crown taxa within the Protostomia (Drosophila melanogaster and Caenorhabditis elegans) and Deuterostomia (human); therefore, it is obvious that the molecular etiology of diseases within the metazoan animals have a common basis. Hence, the major challenge for scientists studying natural product chemistry is to elucidate the target(s) of a given secondary metabolite, which is per se highly active and selective. After this step, the potential clinical application can be approached. The potential value of some selected secondary metabolites, all obtained from sponges and their associated microorganisms, is highlighted. Examples of compounds that are already in medical use (inhibition of tumor/virus growth [arabinofuranosyl cytosine and arabinofuranosyl adenine]), or are being considered as lead structures (acting as cytostatic and anti-inflammatory secondary metabolites [avarol/avarone], causing induction of apoptosis [sorbicillactone]) or as prototypes for the interference with metabolic pathways common in organisms ranging from sponges to humans (modulation of pathways activated by fungal components [aeroplysinin], inhibition of angiogenesis [2-methylthio-1,4-napthoquinone], immune modulating activity [FK506]) are discussed in this study. In addition, bioactive proteins from sponges are listed (antibacterial activity [pore-forming protein and tachylectin]). Finally, it is outlined that the skeletal elements-the spicules-serve as blueprints for new biomaterials, especially those based on biosilica, which might be applied in biomedicine. These compounds and biomaterials have been isolated/studied by members of the German Center of Excellence BIOTECmarin. The goal for the future is to successfully introduce some of these compounds in the treatment of human diseases in order to raise the public awareness on the richness and diversity of natural products, which should be sustainably exploited for human benefit.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.